732. Determination of Vancomycin in Human Cerebrospinal Fluid and Serum by High-Pressure Liquid Chromatography: A Prospective Study
Session: Poster Abstract Session: Antimicrobials: PK/PD Studies
Friday, October 4, 2013
Room: The Moscone Center: Poster Hall C
Background:

Penetration and concentration of vancomycin is still an elusive and complex issue particularly in Cerebrospinal Fluid (CSF). The aim of this study was to clarify the penetration of this antimicrobial agent in CSF during meningeal inflammation.

Methods:

In a prospective study, adult patients, with clinical and CSF analysis compatible with acute meningitis, who received vancomycin (15mg/kg loading and 30mg/kg daily maintenance dose) with ceftriaxone (4 gr/daily) were enrolled. CSF analysis including vancomycin trough levels before the fourth maintenance dose and during the 8-10th days of treatment, and simultaneous serum levels were performed by High-Pressure Liquid Chromatography (HPLC).

Results:

Twenty-seven patients (18 men, 9 women; mean age of 39.4±14.7) were enrolled. The first serum trough level of vancomycin was 13.76±1.29 mg/L. The mean of corresponding trough level in CSF was 11.1±1.42 mg/L. The serum and CSF trough levels revealed positive linear correlation (r: 0.60) and was significant at the 0.01 level (P: 0.004). The penetration CSF/serum ratio was 0.811±0.082 (coefficient of variation: 10.1%).

The second trough levels of serum and CSF in (14 patients) vancomycin were 13.32±1.02 and 10.64±1.21, respectively. The serum and CSF trough levels revealed positive linear correlation (r: 0.71). The serum and CSF concentrations revealed no variation compared to the first trough levels.

Conclusion:

Vancomycin has appropriate concentration in CSF during the treatment of meningitis and do not decrease along with the alleviation of meningeal inflammation in spite of concerns in this regard.

Shervin Shokouhi, MD, Infectious Diseases and Tropical Medicine Research Center (IDTMRC), Shahid Beheshti University of Medical Sciences, Tehran, Iran and Ilad Alavi Darazam, M.D., Departement of Infectious Disease, Shahid Beheshti University of Medical Sciences, Tehran, Iran; Nritld, National Research Institute of Tuberculosis and Lung Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran; Infectious Diseases and Tropical Medicine Research Center (IDTMRC), Shahid Beheshti University of Medical Sciences, Tehran, Iran, Tehran, Iran

Disclosures:

S. Shokouhi, Infectious Diseases and Tropical Medicine Research Center (IDTMRC), Shahid Beheshti University of Medical Sciences, Tehran, Iran: Board Member, Research grant

I. Alavi Darazam, Infectious Diseases and Tropical Medicine Research Center (IDTMRC), Shahid Beheshti University of Medical Sciences, Tehran, Iran: Member, Research grant

Findings in the abstracts are embargoed until 12:01 a.m. PST, Oct. 2nd with the exception of research findings presented at the IDWeek press conferences.